ROCHE HOLDING LTD - 02 Nov 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: 10%+ Owner
Issuer ticker: TRDA
Reported as of: 02 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2021, 21:45:27 UTC
Prior SEC filing: 28 Oct 2021
Next SEC filing: 26 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Jared Cohen, as Attorney-in-Fact

Key filing fact

ROCHE HOLDING LTD filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 04 Nov 2021.

Key facts

This page summarizes ROCHE HOLDING LTD's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Nov 2021, 21:45.

Change

Previous filing in this sequence was filed on 28 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRDA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,495,385
Change %
Price
Shares after: 2,495,385
Date: 02 Nov 2021
Ownership: See Footnote
Footnotes: F1, F2

TRDA transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +318,140
Change %: +13%
Price
Shares after: 2,813,525
Date: 02 Nov 2021
Ownership: See Footnote
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRDA transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -2,495,385
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 2,495,385
Exercise price
Footnotes: F1, F2

TRDA transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -318,140
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 318,140
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.

Footnote F2

Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.